Stockscreener 앱 받기
5.535
2.12%
0.115
전일 마감가:
$5.42
열려 있는:
$5.42
하루 거래량:
7,868
Relative Volume:
0.15
시가총액:
$12.94M
수익:
-
순이익/손실:
$-4.85M
주가수익비율:
-17.85
EPS:
-0.31
순현금흐름:
$-3.95M
1주 성능:
-2.89%
1개월 성능:
-36.16%
6개월 성능:
-52.61%
1년 성능:
-71.16%
1일 변동 폭
$5.42
$5.6763
1주일 범위
$5.385
$6.105
52주 변동 폭
$5.34
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
명칭
Cadrenal Therapeutics Inc
전화
904-300-0701
주소
822 A1A NORTH, PONTE VEDRA
Compare CVKD vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
5.535 | 12.67M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-18 | 개시 | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc 주식(CVKD)의 최신 뉴스
What is Cadrenal Therapeutics Inc. s revenue forecastJuly 2025 Chart Watch & Weekly High Return Stock Opportunities - mfd.ru
Can Cadrenal Therapeutics Inc. weather a recessionJuly 2025 Selloffs & Weekly Chart Analysis and Guides - mfd.ru
Is Cadrenal Therapeutics Inc. stock a safe haven assetWeekly Trend Report & Smart Allocation Stock Tips - mfd.ru
Fed Meeting: Can Cadrenal Therapeutics Inc stock double in the next yearIndex Update & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 0.4% – What’s Next? - Defense World
(CVKD) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Profit Review: Will Cadrenal Therapeutics Inc outperform its industry peersMarket Risk Analysis & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Update Recap: Will Cadrenal Therapeutics Inc outperform its industry peersJuly 2025 Opening Moves & Verified Momentum Stock Ideas - baoquankhu1.vn
Cadrenal Therapeutics expands at-the-market stock offering capacity - MSN
(CVKD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Aug Momentum: Is Cadrenal Therapeutics Inc stock overvalued or fairly pricedMarket Volume Summary & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Why is Cadrenal Therapeutics stock drawing retail attention today? - MSN
Why Is Cadrenal Therapeutics Stock Drawing Retail Attention Today? - Asianet Newsable
Cadrenal Advances Anticoagulation Pipeline, VLX-1005 Completes Phase 2 Trial - intellectia.ai
(CVKD) Risk Channels and Responsive Allocation - Stock Traders Daily
CVKD: VLX-1005 and Tecarfarin lead a strategy to address unmet needs in rare anticoagulation markets - TradingView — Track All Markets
CVKD: VLX-1005 and tecarfarin drive innovation in underserved anticoagulation markets, with key milestones ahead - TradingView — Track All Markets
Trend Report: Can GMGI stock double in the next yearJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - baoquankhu1.vn
Income Plays: Is Cadrenal Therapeutics Incs ROIC above industry averageEarnings Miss & Fast Moving Stock Watchlists - baoquankhu1.vn
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder By Investing.com - Investing.com Nigeria
Cadrenal highlights potential of 12-LOX inhibitor for blood disorder - Investing.com
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX In - GlobeNewswire
Cadrenal Therapeutics, Inc. - MSN
Will Cadrenal Therapeutics Inc. stock keep outperforming rivals2025 Key Highlights & Community Verified Watchlist Alerts - Улправда
Will Cadrenal Therapeutics Inc. stock benefit from commodity pricesWeekly Trend Summary & Real-Time Volume Trigger Notifications - Улправда
Can Cadrenal Therapeutics Inc. stock deliver consistent earnings growthMarket Performance Summary & Weekly Consistent Profit Watchlists - Улправда
What sentiment indicators say about Cadrenal Therapeutics Inc. stockMarket Growth Report & Weekly Market Pulse Updates - Улправда
Risk Analysis: Why Cadrenal Therapeutics Inc. stock remains undervaluedBreakout Watch & Daily Profit Maximizing Tips - ulpravda.ru
How Cadrenal Therapeutics Inc. stock trades during market volatilityJuly 2025 Institutional & Stepwise Trade Execution Plans - Улправда
Is Cadrenal Therapeutics Inc. stock a contrarian buyTrade Performance Summary & Step-by-Step Swing Trade Plans - Улправда
Cadrenal Therapeutics acquires VLX-1005 from Veralox - MSN
(CVKD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Cadrenal Therapeutics, Inc. Common Stock (CVKD) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Matthew Szot Sells 9,933 Shares of Cadrenal Therapeutics (NASDAQ:CVKD) Stock - Defense World
Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System - The Globe and Mail
How a small biotech is building an emergency anticoagulation plan - Stock Titan
Cadrenal Therapeutics announces new securities purchase agreement - MSN
Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On - ACCESS Newswire
Inside the drug startup rebuilding blood thinners for medicine’s toughest cases - Stock Titan
(CVKD) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cadrenal Therapeutics Expands At-The-Market Stock Offering Capacity - The Globe and Mail
Cadrenal Therapeutics Appoints Dr. Golden to Board - MSN
Cadrenal Therapeutics (NASDAQ:CVKD) & Biodexa Pharmaceuticals (NASDAQ:BDRX) Financial Analysis - Defense World
Downgrade Watch: Will Cadrenal Therapeutics Inc stock benefit from commodity pricesEarnings Beat & Detailed Earnings Play Alerts - moha.gov.vn
Is Cadrenal Therapeutics Inc. stock attractive for long term wealth buildingJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - ulpravda.ru
How Cadrenal Therapeutics Inc. stock performs in stagflation2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Cadrenal Therapeutics Inc (CVKD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):